Advocacy intelligence hub — real-time data for patient organizations
Xolremdi: FDA approved
to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)
X4 Pharmaceuticals — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Xolremdi
X4 Pharmaceuticals, Inc.
Xolremdi
(mavorixafor)Orphan drugX4 Pharmaceuticals, Inc.
CXC Chemokine Receptor 4 Antagonist [EPC]
12.1 Mechanism of Action Mavorixafor is an orally bioavailable CXCR4 antagonist that blocks the binding of the CXCR4 ligand, stromal-derived factor-1α...